NeoGenomics, Inc. (BMV:NEO)
| Market Cap | 36.54B +49.7% |
| Revenue (ttm) | 14.20B +11.1% |
| Net Income | -582.10M |
| EPS | -4.80 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 49.75 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 339.00 |
| Previous Close | 339.00 |
| Day's Range | 339.00 - 339.00 |
| 52-Week Range | 176.40 - 339.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 28, 2026 |
About NeoGenomics
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and ge... [Read more]
Financial Performance
In 2025, NeoGenomics's revenue was $727.33 million, an increase of 10.11% compared to the previous year's $660.57 million. Losses were -$108.03 million, 37.2% more than in 2024.
Financial numbers in USD Financial StatementsNews
NeoGenomics Transcript: 2026 Stephens Annual Investment Conference | NASH2026
Q3 clinical growth was 13%, led by NGS growth of 29%, and adjusted EBITDA rose 53% YoY. Management sees continued NGS momentum, expanding RaDaR coverage and further gross-margin improvement in 2027.
NeoGenomics to Participate in Upcoming Investor Conferences
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will participate in the Stephens Annual Investment Conference and the Piper Sandler 38th Annual Healthcare Conference.
NeoGenomics price target raised to $23 from $19 at TD Cowen
TD Cowen analyst Dan Brennan raised the firmās price target on NeoGenomics (NEO) to $23 from $19 and keeps a Buy rating on the shares. The firm said its Q3ā¦
NeoGenomics price target raised to $21 from $16.50 at Jefferies
Jefferies raised the firmās price target on NeoGenomics (NEO) to $21 from $16.50 and keeps a Buy rating on the shares after the company reported better-than-expected Q3 results and raisedā¦
NeoGenomics reports Q3 adjusted EPS 7c, consensus 6c
Reports Q3 revenue $209M, consensus $207.33M. āOur third-quarter results reinforce that we have the right strategy in place and the right team to execute against it,ā said Tony Zook, Chiefā¦
NeoGenomics raises FY26 revenue view to $807M-$809M from $802M-$806M
Consensus $805.2M. Raises FY26 adjusted EBITDA roughly $60M from $56M-$58M.
NeoGenomics Earnings Call Transcript: Q3 2026
Q3 revenue grew 11% and NGS grew 29%, supporting higher 2026 revenue and adjusted EBITDA guidance. Margin expansion, reimbursement progress, and investment in NGS and MRD underpin the outlook, alongside collection and reimbursement risks.
NeoGenomics Earnings release: Q3 2026
NeoGenomics released its Q3 2026 earnings on October 28, 2026, summarizing the period's financial results.
NeoGenomics Slides: Q3 2026
NeoGenomics has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on October 28, 2026.
NeoGenomics Quarterly report: Q3 2026
NeoGenomics has published its Q3 2026 quarterly earnings report on October 28, 2026.
NeoGenomics Reports Third Quarter 2026 Results
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced its third-quarter results for the period ended September 30, 2026.
NeoGenomics expands partnership with Indica Labs
NeoGenomics (NEO) has expanded its partnership with Indica Labs. The collaboration is intended to scale NeoGenomicsā digital pathology infrastructure and accelerate AI-driven diagnostics across its en...
NeoGenomics Expands Indica Labs Partnership to Scale AI-Powered Digital Pathology
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics expanded its partnership with Indica Labs to scale AI-powered digital pathology and support more timely, consistent diagnostic insights.
NeoGenomics to Report Third Quarter 2026 Financial Results on October 28, 2026
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will report its third quarter 2026 financial results after the close of the U.S. financial markets on Wednesday, October 28, 2026.
NeoGenomics price target raised to $20 from $16 at BofA
BofA raised the firmās price target on NeoGenomics (NEO) to $20 from $16 and keeps a Neutral rating on the shares. While Neogenomicsā disclosure yesterday of a CEO transition ācameā¦
NeoGenomics price target raised to $20 from $16 at StoneX
StoneX analyst Bruce Jackson raised the firmās price target on NeoGenomics (NEO) to $20 from $16 and keeps a Buy rating on the shares following the companyās āpositiveā Q3 preannouncementā¦
NeoGenomics upgraded to Buy from Neutral at BTIG
BTIG upgraded NeoGenomics (NEO) to Buy from Neutral with a $28 price target The shares are up 62% year-to-date but trade at just 3-times the 2027 consensus revenue estimate, theā¦
NeoGenomics down 2% at $18.73 after Q3 pre-announcement, CEO transition
16:44 EDT NeoGenomics (NEO) down 2% at $18.73 after Q3 pre-announcement, CEO transition
NeoGenomics sees Q3 revenue of about $209M, consensus $205.9M
The company states: āAlthough NeoGenomics (NEO) has not finalized its financial results as of and for the quarter ended September 30, 2026, NeoGenomics expects to report third quarter total revenueā¦
NeoGenomics names Warren Stone as new CEO effective 2027
The company states: āNeoGenomics (NEO) announced that as part of a planned succession, its Board of Directors has appointed Warren Stone, current President and Chief Operating Officer (COO), as Chiefā¦
NeoGenomics Announces Executive Leadership and Board of Directors Succession Plan
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics today announced its executive leadership and board of directors succession plan.
NeoGenomics Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Focused on community oncology, the company leverages a broad portfolio and workflow solutions to drive growth, with NGS revenue expanding at 26% and new products like PanTracer and RaDaR ST strengthening its competitive edge. Strategic investments in R&D, sales, and IT infrastructure support continued margin and cash flow improvements.
NeoGenomics to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will participate in the Morgan Stanley 24th Annual Global Healthcare Conference, Sept. 14ā16, 2026, in New York.
NeoGenomics receives Medicare coverage for RaDaR ST MRD assay
NeoGenomics (NEO) announced that its RaDaR ST molecular residual disease assay has received expanded coverage from the Centers for Medicare & Medicaid Servicesā Molecular Diagnostic Services Program t...
NeoGenomics Receives Medicare Coverage for RaDaR ST for Immunotherapy Treatment Response Monitoring
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced expanded MolDX coverage for its RaDaRĀ® ST MRD assay for immunotherapy monitoring in late-stage solid tumors.